Robert S Alter MD
Genitourinary Oncology, Head & Neck Cancer
Co-Chief of Urologic and Head & Neck Oncology at John Theurer Cancer Center
Join to View Full Profile
92 2nd StHackensack, NJ 07601
Phone+1 551-996-5072
Fax+1 551-996-0719
Dr. Alter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1991 - 1994
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1988 - 1991
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1988
Certifications & Licensure
FL State Medical License 1997 - 2027
NY State Medical License 1989 - 2026
NJ State Medical License 1996 - 2025
PA State Medical License 2002 - 2017
CT State Medical License 1994 - 1997
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2009 Oct 01
- Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
- LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Start of enrollment: 2014 Jul 01
Publications & Presentations
PubMed
- Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede
Cancer Discovery. 2025-02-24 - 3 citationsTreatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohor...Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen
Journal for Immunotherapy of Cancer. 2024-04-11 - 12 citationsPhase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen
Journal for Immunotherapy of Cancer. 2023-03-01
Professional Memberships
- Member
- Member
Other Languages
- Hebrew
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
